Globally, about one in four people over the age of 25 will suffer a stroke in their lifetime [2]. Nearly a third of Ischemic strokes - the result of blood clots that block the flow of blood to the brain - are classified as cryptogenic, meaning the cause is unknown [3]. These situations require post-stroke diagnostic work to determine the cause and prevent a second stroke from occurring. AF is a common cause and can increase the risk of stroke by more than five times [4], but it often goes undetected since it can be asymptomatic and may occur infrequently.
The study evaluated a stroke population of 1,000 for one year to assess the differences in costs and outcomes of two monitoring options that are available to clinicians today to help improve patient care and improve efficiencies within the healthcare system. Findings revealed using an
This new research confirms that using Philips BioTel Heart MCOT as the first line of evaluation is more cost-effective and can provide the level of diagnostic confidence needed to help detect and diagnose atrial fibrillation, and potentially prevent a second stroke.
General Manager of Ambulatory Monitoring and Diagnostics at Philips
'The diagnostic tools clinicians use to monitor this group of patients play an important role in finding the cause of the stroke and developing a personalized treatment plan,' said
Patients were monitored for 30 days and were included in one of two monitoring arms in the model: The
Philips solutions across care pathways
Philips offers a complete portfolio of clinically validated ambulatory cardiac diagnostic and monitoring services as well as stroke care solutions that provide industry-leading data analysis and management to help make care delivery more comprehensive, accurate and efficient. These solutions aim to connect information, technologies and people across both the stroke and cardiac care pathways, enabling care teams to work quickly and act decisively to provide the best patient treatment. The new research results illustrate the company's strong commitment to further innovation in this field.
For more information on Philips' full portfolio of cardiology solutions being showcased during the
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in
Contact:
Philips Global Press Office
Tel: +1 724-584-8991
(C) 2022 Electronic News Publishing, source